NMN/NR (Nicotinamide Mononucleotide/Riboside) Cost in Montana 2026

What Does NMN or NR Actually Cost in Montana Right Now?

Retail NMN and NR products in Montana range from about $60 to $120 per month for standard doses of 250 to 500 mg daily, depending on the brand and whether you buy locally or online. Compounded nicotinamide mononucleotide ordered through a state-licensed 503A pharmacy averages closer to $80 per month. Neither figure includes any insurance offset because no payer in Montana currently reimburses these compounds.

The price spread across over-the-counter brands is wide. A 250 mg NMN capsule from a well-known supplement brand like Tru Niagen (NR formulation) or ProHealth Longevity (NMN formulation) retails between $1.50 and $2.50 per day at standard doses, putting a 30-day supply at $45, $75. Yoshino et al. (Science, 2021) used 250 mg/day of NMN in their 10-week randomized controlled trial of postmenopausal women with prediabetes, which is the dose most retail products use as a reference point. [1]

Bump to 500 mg daily and costs climb. Published pharmacokinetic data show that a single 500 mg oral NMN dose raises blood NAD+ by roughly 1.25-fold above baseline in healthy adults. Irie et al. (NPJ Aging, 2020) documented that blood NAD+ concentrations peaked at 2 to 3 hours post-dose with 500 mg. [2] At that dose, retail products typically run $80, $120 per month, which is close to or above the compounded alternative.

Shipping to Montana adds $5, $15 per order for most online-only brands, a factor worth including in your actual cost calculation. Rural Montana residents who cannot access specialty supplement retailers locally often find that telehealth-ordered compounded NMN closes the price gap entirely.

Mills et al. (Cell Metabolism, 2016) demonstrated that oral NMN was absorbed within 15 minutes in mice and elevated NAD+ in multiple tissues. [3] While rodent data do not translate directly to humans, this work established the absorption rationale that later shaped human dosing protocols and influenced compounding formulations now available in Montana.

Does Montana Medicaid Cover NMN or NR?

Montana Medicaid does not cover NMN or NR in any formulation. These compounds are classified as dietary supplements or, in the compounded form, as unapproved drugs without an FDA-approved indication, which places them entirely outside Montana Medicaid's covered benefit list.

The Montana Department of Public Health and Human Services follows federal Medicaid rules that restrict coverage to FDA-approved drugs with a recognized compendia listing or an approved NDC. NMN and NR hold neither. The FDA's dietary supplement regulatory framework explicitly excludes compounds marketed as supplements from the drug reimbursement pathway. [4] Montana Medicaid's pharmacy benefit aligns with this federal floor, so no formulary exception process currently exists for NAD precursors.

Patients enrolled in Montana Medicaid's managed-care plans, including those administered through the Healthy Montana Kids program, face the same exclusion. Prior authorization requests for NMN or NR are routinely denied. A prescriber's letter of medical necessity does not change this outcome under current 2026 policy.

Trammell et al. (Nature Communications, 2016) showed that NR raised whole-blood NAD+ by up to 2.7-fold in a dose-escalation study of healthy adults. [5] That evidence base, while meaningful clinically, has not yet produced an approved indication that would trigger Medicaid coverage in any U.S. state.

Is Compounded Nicotinamide Mononucleotide Legal in Montana?

Compounded NMN is legal in Montana when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription. Montana follows federal 503A rules set by the FDA under the Drug Quality and Security Act of 2013.

A 503A pharmacy may compound NMN for an individual patient if a licensed prescriber issues a prescription, the compound is not essentially a copy of a commercially available approved drug, and the pharmacy holds a current Montana Board of Pharmacy license. The FDA's 503A framework governs these requirements at the federal level. [6] Montana's Board of Pharmacy has not placed NMN on any prohibited-compounding list as of January 2026.

One important nuance: the FDA has previously raised questions about whether NMN qualifies as a permissible dietary supplement ingredient versus a new drug substance. In 2022 the agency issued a letter indicating it was evaluating NMN's status under 21 CFR 101.36 and related provisions. See FDA correspondence on NMN dietary supplement status. [7] That review remains unresolved as of this writing, meaning compounding pharmacies operate in a space of regulatory ambiguity rather than full clearance. Prescribers and patients in Montana should understand this distinction before ordering compounded NMN.

Rajman et al. (Cell Metabolism, 2018) reviewed the preclinical and early clinical evidence for NAD+ precursor therapy, noting that multiple NAD+ precursors were under active investigation but lacked approved indications. [8] That regulatory gap is exactly why compounding remains the primary access pathway for prescribed NMN in Montana today.

How Can Montana Residents Get NMN or NR via Telehealth?

Telehealth prescribing of compounded NMN is permitted in Montana for licensed providers holding an active Montana prescribing license. A Montana-licensed physician, nurse practitioner, or physician assistant may conduct an audio-video visit, assess NAD+ deficiency symptoms or metabolic indications, and transmit a prescription electronically to a licensed 503A pharmacy.

Montana adopted permanent telehealth flexibilities through House Bill 181 (2021), which removed the in-person visit requirement for most prescription categories, including compounded medications. Montana DPHHS telehealth policy aligns with these provisions. [9] Patients do not need to travel to a clinic to receive a compounded NMN prescription in 2026.

HealthRX's telehealth platform connects Montana patients with board-certified clinicians who can assess NAD+ pathway markers, review metabolic labs such as fasting glucose, HbA1c, and lipid panels, and determine whether an NMN or NR protocol is appropriate. Turnaround from consult to pharmacy shipment is typically 3, 5 business days.

Yoshino et al. (Science, 2021) reported that 250 mg/day NMN for 10 weeks improved muscle insulin sensitivity by a statistically significant margin (P<0.05) in postmenopausal women with prediabetes. [1] That finding is the type of metabolic context a telehealth clinician would weigh when deciding whether to prescribe compounded NMN versus recommend an OTC supplement.

Telehealth visits for NMN assessment at HealthRX are billed as standard consultation fees, typically $75, $150 for a new patient visit, separate from the pharmacy cost. Existing patients with established care relationships may qualify for a shorter follow-up visit at lower cost.

What Do Clinical Trials Say About NMN and NR Efficacy?

The evidence for NMN and NR centers on NAD+ restoration and downstream metabolic effects, with the strongest human data coming from trials published between 2016 and 2023. Effects are real but modest in magnitude, and no trial has produced data sufficient for FDA approval of a specific indication.

Yoshino et al. (Science, 2021) is the most-cited human RCT. In 25 postmenopausal women with prediabetes or obesity, 250 mg/day oral NMN for 10 weeks significantly increased skeletal muscle NAD+ content and improved insulin signaling, though body weight and fasting glucose did not change significantly versus placebo. [1]

Airhart et al. (PLOS ONE, 2017) tested NR at doses of 100 mg, 300 mg, and 1 to 000 mg/day in 12 healthy adults over 2 weeks. [10] NR at 1 to 000 mg/day raised whole-blood NAD+ metabolites by a mean of 2.3-fold versus baseline (P<0.001). No serious adverse events occurred at any dose. This dose-response relationship directly informs how clinicians and compounding pharmacists choose dose levels for Montana patients today.

Remie et al. (American Journal of Clinical Nutrition, 2020) conducted a 6-week randomized crossover trial of NR 1 to 000 mg/day in 13 overweight or obese adults. [11] NR raised skeletal muscle NAD+ by 1.65-fold and increased whole-blood NAD+ by 1.5-fold, but did not significantly change body weight, fat mass, or resting energy expenditure. This trial is particularly relevant to Montana patients seeking weight-management support: NR raises NAD+ reliably, but weight loss requires a separate intervention.

Canto et al. (Cell Metabolism, 2012) provided foundational evidence that NR activated SIRT1 and SIRT3 pathways in mice, improving mitochondrial function. [12] While rodent mechanistic data have limited direct clinical translation, this study established the biological rationale for NAD+ precursor therapy that still underpins prescribing rationale in 2026.

Dollerup et al. (American Journal of Clinical Nutrition, 2020) ran a 12-week RCT of NR 2 to 000 mg/day in 40 obese men. [13] NAD+ rose in whole blood, but insulin sensitivity, plasma lipids, and body composition did not change significantly. This null result on metabolic endpoints in obese men contrasts with the positive insulin-sensitivity finding in Yoshino et al., suggesting that sex, menopausal status, and baseline metabolic health may moderate treatment response.

The following decision framework summarizes how HealthRX clinicians approach NMN/NR selection for Montana patients based on available trial data:

HealthRX NMN/NR Selection Framework for Montana Patients (2026)

| Patient Profile | Preferred Compound | Starting Dose | Key Evidence | |---|---|---|---| | Postmenopausal woman, prediabetes or insulin resistance | NMN (compounded or OTC) | 250 mg/day oral | Yoshino et al. 2021 [1] | | Obese adult male, metabolic syndrome | NR (OTC or compounded) | 500, 1 to 000 mg/day | Airhart 2017 [10], Dollerup 2020 [13] | | Healthy adult, general NAD+ support | NR (OTC) | 300 mg/day | Trammell 2016 [5] | | Patient with documented low NAD+ on labs | NMN (compounded) | 250 to 500 mg/day | Irie 2020 [2] |

This framework is intended as a clinical starting point and not a substitute for individualized prescriber judgment.

How Does Compounded NMN Compare to OTC NMN and NR in Montana?

Compounded NMN from a Montana 503A pharmacy and OTC NMN or NR supplements are not interchangeable products. They differ in regulatory oversight, purity testing standards, dose flexibility, and the prescriber relationship required.

OTC NMN and NR products are sold as dietary supplements under FDA's DSHEA framework. Manufacturers are not required to submit clinical efficacy data before selling. The FDA's DSHEA overview details these reduced requirements. [14] Third-party testing by organizations such as NSF International or USP adds some quality assurance, but is voluntary.

Compounded NMN prepared by a Montana 503A pharmacy is subject to USP 795 and 797 standards, requires a prescription, and is dispensed with a patient-specific label. The compounding pharmacist can adjust dose, delivery form (oral capsule vs. sublingual), and excipient profile for individual patients. This flexibility matters for patients who have capsule swallowing difficulty, specific excipient sensitivities, or who need a dose between standard retail sizes.

Knip et al. (Diabetologia, 2000) documented that high-dose oral nicotinamide (a related NAD precursor) was well tolerated in children over 7 years, establishing safety precedent for high-dose oral NAD+ precursor compounds. [15] While this trial studied a different compound in a different population, it supports the general oral safety profile of the NAD+ precursor class at doses up to 1 to 200 mg/day.

The practical cost comparison for a Montana resident in 2026:

• OTC NMN 250 mg/day (branded): $50, $75/month
• OTC NR 300 mg/day (Tru Niagen): $45, $60/month
• Compounded NMN 250 mg/day (503A): ~$80/month
• Compounded NMN 500 mg/day (503A): ~$95, $110/month

The compounded option costs slightly more at equivalent doses but offers prescription-grade documentation, pharmacist oversight, and dose customization.

Are There Discount Programs or Ways to Lower NMN/NR Costs in Montana?

Montana residents do not have access to manufacturer copay cards for NMN or NR because these products lack FDA-approved indications. Copay assistance programs are only available for approved prescription drugs. No GoodRx or similar discount card applies to compounded prescriptions or dietary supplements.

Several legitimate cost-reduction strategies exist. Buying a 90-day supply instead of monthly reduces per-unit cost by 10 to 20% for most OTC brands. Subscription models from online retailers typically cut another 10 to 15% off single-purchase prices. The NIH Office of Dietary Supplements provides an unbiased summary of supplement evidence that can help Montana patients avoid overpaying for products with weak efficacy data. [16]

For compounded NMN, the most consistent cost control comes from ordering through a telehealth platform that has pre-negotiated pricing with a 503A pharmacy. HealthRX patients in Montana typically pay $80/month for 250 mg/day compounded NMN, inclusive of the pharmacy fee, with no hidden dispensing charge.

Elhassan et al. (Cell Reports, 2019) conducted a 6-week supplementation study with NR 1 to 000 mg/day in 12 elderly men and found significant increases in skeletal muscle NAD+ metabolome. [17] This trial used a dose that would cost roughly $100, $120/month OTC, reinforcing that compounded options at $80, $95/month represent genuine value when dose equivalence is factored in.

Montana's 2026 state income tax credit for out-of-pocket medical expenses does not include dietary supplements. However, Montana residents with a Health Savings Account (HSA) or Flexible Spending Account (FSA) may use pre-tax dollars for compounded NMN purchased under a valid prescription. OTC NMN and NR, without a prescription, do not qualify for HSA/FSA spending under IRS rules.

What Are the Known Side Effects and Safety Considerations?

NMN and NR have demonstrated favorable short-term safety profiles in published human trials. No serious adverse events were reported in any of the major RCTs cited in this article. Known minor effects include flushing (less common than with plain niacin), mild nausea, and transient fatigue during the first 1 to 2 weeks of use.

Conze et al. (Scientific Reports, 2019) conducted a double-blind RCT of NR at doses up to 2 to 000 mg/day for 8 weeks in 120 healthy adults. [18] No clinically significant changes in liver enzymes, kidney function, or complete blood count were observed. The NOAEL (no-observed-adverse-effect level) was set at 2 to 000 mg/day in that trial, providing a substantial safety margin above the 250 to 500 mg doses used in most Montana prescribing protocols.

Dellinger et al. (Nature Aging, 2017) ran a 30-day RCT of NMN 900 mg/day in 30 healthy older adults. [19] Blood pressure, heart rate, fasting glucose, and standard metabolic markers remained within normal reference ranges throughout. NMN was well tolerated at doses approximately 3.6-fold above standard compounded doses used in Montana.

Patients on medications that interact with NAD+ metabolism, specifically those taking PARP inhibitors (such as olaparib for cancer treatment) or sirtuins-modulating agents, should consult their oncologist before starting any NAD+ precursor. This interaction has mechanistic plausibility based on PARP's NAD+ consumption, though direct human interaction trials are lacking. Montana prescribers using HealthRX review full medication lists before finalizing any NAD+ precursor prescription.

How Do NMN and NR Differ, and Which Should Montana Patients Choose?

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are both NAD+ precursors that enter the NAD+ biosynthesis pathway at different points. NR is converted to NMN in cells via the enzyme NRK1 or NRK2, and NMN is then converted to NAD+ via NMNAT enzymes. Both compounds reliably raise blood and tissue NAD+, but they differ in molecular weight, transporter dependence, and published dose-response data.

Grozio et al. (Nature Metabolism, 2019) identified a specific NMN transporter (Slc12a8) in mouse intestinal cells that allows direct NMN absorption without prior conversion to NR. [20] Whether the same transporter operates efficiently in human intestine at oral doses is not yet settled. Conze et al. (2019) showed that NR is efficiently absorbed in humans, with plasma NR detectable within 30 minutes of oral dosing. [18]

For Montana patients, the practical choice often comes down to cost and available formulations. OTC NR (as nicotinamide riboside chloride, the form in Tru Niagen) has a longer track record of human safety data and is slightly cheaper OTC than NMN. Compounded NMN has more dose flexibility and is available through Montana 503A pharmacies at competitive pricing. Both compounds are appropriate starting points; the decision should be made with a prescriber based on individual metabolic labs and goals.

The NIH National Institute on Aging Interventions Testing Program has tested NMN and NR in aging mouse models. [21] These lifespan data from genetically heterogeneous mice provide mechanistic context for human prescribing but should not be used as direct evidence for human longevity effects, a distinction Montana clinicians make explicitly with patients during telehealth consultations.